Markets:

Overview

News

Currencies

International

Treasuries

REGENXBIO Inc. - Common Stock (NQ:RGNX)

8.350 -0.150 (-1.76%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about REGENXBIO Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Where Regenxbio Stands With Analysts ↗

August 05, 2024

Via Benzinga

Why Is Clearside Biomedical Stock Gaining Today? ↗

June 25, 2024

Clearside Biomedical pioneers suprachoroidal drug delivery for precise, effective treatment of retinal diseases. Oppenheimer rates CLSD Outperform with a $5 target, citing its innovative SCS...

Via Benzinga

7 Biotech Stocks to Buy on the Dip: June 2024 ↗

June 24, 2024

With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.

Via InvestorPlace

FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy ↗

June 21, 2024

The FDA has approved Sarepta Therapeutics' Elevidys for treating Duchenne muscular dystrophy in patients aged 4 and older with specific DMD gene mutations.

Via Benzinga

Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy ↗

June 20, 2024

The agency signed off on Elevidys for a broad population of children with the muscle-wasting disease.

Via Investor's Business Daily

Assessing Regenxbio: Insights From 4 Financial Analysts ↗

June 07, 2024

Via Benzinga

Evaluating Regenxbio: Insights From 9 Financial Analysts ↗

May 15, 2024

Via Benzinga

Where Regenxbio Stands With Analysts ↗

April 12, 2024

Via Benzinga

Beyond The Numbers: 4 Analysts Discuss Regenxbio Stock ↗

March 06, 2024

Via Benzinga

Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test ↗

June 13, 2024

Sarepta is now just awaiting the FDA's decision on whether to fully approve its gene therapy, and for whom.

Via Investor's Business Daily

Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside ↗

June 07, 2024

Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform.

Via Benzinga

RGNX Stock Earnings: Regenxbio Misses EPS, Misses Revenue for Q1 2024 ↗

May 08, 2024

RGNX stock results show that Regenxbio missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Monday's After-Market Session ↗

March 25, 2024

Via Benzinga

Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling? ↗

March 13, 2024

The threat is still emerging, but it could be significant.

Via The Motley Fool

Regenxbio: Q4 Earnings Insights ↗

February 27, 2024

Via Benzinga

Earnings Scheduled For February 27, 2024 ↗

February 27, 2024

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.

Via Benzinga

A Preview Of Regenxbio's Earnings ↗

February 26, 2024

Via Benzinga

This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO ↗

March 08, 2024

REGENXBIO's promising gene therapy advancements! RBC Capital Markets upgraded REGENXBIO (RGNX), citing impressive RGX-202 trial results in Duchenne patients.

Via Benzinga

REGENXBIO's Muscle Wasting Disorder Drug Shows Strength, Improved Motor Function, Stock Soars ↗

March 05, 2024

Latest updates on safety and efficacy in the Phase 1/2 AFFINITY DUCHENNE trial for Duchenne muscular dystrophy. Positive results, no serious adverse events. Expect pivotal dose determination by...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 05, 2024

Via Benzinga

Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday ↗

March 01, 2024

U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday.

Via Benzinga

Topics Stocks

Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

March 01, 2024

Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results.

Via Benzinga

Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst ↗

February 12, 2024

Insights from Wedbush analysts about the clinical effectiveness of REGENXBIO's RGX-202, market potential, and challenges posed by competitors like Sarepta Therapeutics and Pfizer.

Via Benzinga

The One-Minute Market Report - Sunday, Feb. 11 ↗

February 11, 2024

In this brief market report, we will take a look at the various asset classes, sectors, equity categories, exchange-traded funds, and stocks that moved the market higher, as well as the market segments...

Via Talk Markets

Jim Cramer Says Investors Should Look Beyond Apple, Meta And Other Magnificent 7 Stocks: 'You Might Be Missing Out On Some Huge Gains' ↗

February 08, 2024

Jim Cramer, the host of CNBC's "Mad Money," has suggested that investors should look beyond the Magnificent Seven tech stocks for potential high-yield investments.

Via Benzinga

Why Is Blindness Focused-Adverum Biotechnologies Stock Trading Lower Today? ↗

February 08, 2024

Adverum Biotechnologies' Ixo-vec gene therapy for wet AMD. Preliminary LUNA Phase 2 trial data show safety, efficacy, and significant treatment burden reduction.

Via Benzinga

Why Is Gene Therapy-Focused REGENXBIO Stock Trading Higher Today? ↗

February 07, 2024

REGENXBIO's progress in Duchenne muscular dystrophy and MPS II treatment trials. Interim results for RGX-202 in Phase 1/2 trial and significant milestones achieved in Phase 1/2/3 trial with RGX-121.

Via Benzinga

Chipotle Posts Upbeat Earnings, Joins Cirrus Logic, Emerson Electric, Carlyle Group And Other Big Stocks Moving Higher On Wednesday ↗

February 07, 2024

U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Wednesday.

Via Benzinga

Topics Stocks

Why Container Store Group Shares Are Trading Lower By Around 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

February 07, 2024

Shares of The Container Store Group, Inc. (NYSE: TCS) shares fell sharply during Wednesday’s session following weak quarterly results.

Via Benzinga

Ocular Gene Therapy: Regenxbio Data Shows Consistent Preservation Of Visual Acuity, Retinal Thickness ↗

January 17, 2024

Regenxbio's latest trial data on ABBV-RGX-314 reveal 80% reduction in injection rate, 50% injection-free, and no intraocular inflammation.

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

REGENXBIO Inc. - Common Stock (NQ:RGNX)

All News about REGENXBIO Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today